Major Depressive Disorder
Conditions
Keywords
Depression, MDD
Brief summary
The primary objective of this study is to assess whether LY2216684 12 milligrams (mg) or 18 mg flexible dose once daily is superior to placebo once daily in the adjunctive treatment of participants with major depressive disorder (MDD) who are partial responders to their selective serotonin reuptake inhibitor (SSRI) treatment.
Detailed description
Following the Confirmation (CF) Phase, participants were randomized to adjunctive LY2216684 or adjunctive placebo if they had \<25% improvement in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score over the past 3 weeks and a current MADRS total score ≥14. Participants who did not meet criteria received adjunctive placebo to preserve the blind.
Interventions
Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
Sponsors
Study design
Eligibility
Inclusion criteria
* Women of child-bearing potential may participate but must test negative for pregnancy at the time of study entry; both women/men agree to use a reliable method of birth control * Are being treated with one of the following selective serotonin reuptake inhibitors (SSRIs): escitalopram, citalopram, sertraline, fluoxetine, paroxetine, or fluvoxamine; for at least 6 weeks prior to investigational product dispensing with at least the last 4 weeks at a stable, optimized dose * Drug and dosage should be within the labeling guidelines for the specific country * Meet criteria for major depressive disorder (MDD), as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision® (DSM-IV-TR) criteria * Meet criteria for partial response, as defined by investigator's opinion that the participant has experienced a minimal clinically meaningful improvement with SSRI * Have a GRID 17-Item Hamilton Depression Rating Scale (GRID-HAMD17) total score greater than or equal to 16 at screening * Have less than or equal to 75% improvement on the current SSRI at screening determined by the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ)
Exclusion criteria
* Have had or currently have any additional ongoing DSM-IV-TR Axis 1 condition other than major depression within 1 year of screening * Have had any anxiety disorder that was considered a primary diagnosis within the past year (including panic disorder, obsessive-compulsive disorder \[OCD\], post-traumatic stress disorder \[PTSD\], generalized anxiety disorder \[GAD\], and social phobia, but excluding specific phobias) * Have a current or previous diagnosis of a bipolar disorder, schizophrenia, or other psychotic disorder * Have a history of substance abuse and/or dependence within the past year (drug categories defined by DSM-IV-TR), not including caffeine and nicotine * Have an Axis II disorder that, in the judgment of the investigator, would interfere with compliance with protocol * Unstable medical conditions that contraindicate the use of LY2216684 * Have any diagnosed medical condition that could be exacerbated by noradrenergic agents, including unstable hypertension, unstable heart disease, tachycardia, tachyarrhythmia, narrow-angled glaucoma, history of urinary hesitancy or retention * Use of excluded concomitant or psychotropic medication other than SSRI * Have initiated or discontinued hormone therapy within the 3 months prior to enrollment * History of treatment-resistant depression as shown by lack of response of the current depressive episode to 2 or more adequate courses of antidepressant therapy at a clinically appropriate dose for at least 4 weeks or, in the judgment of the investigator, the participant has treatment-resistant depression * Have a lifetime history of vagal nerve stimulation (VNS), transcranial magnetic stimulation (TMS), or psychosurgery * Have received electroconvulsive therapy (ECT) in the past year
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | Randomization, 8 weeks | The Montgomery-Asberg Depression Rating Scale (MADRS) is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Impact Subscale Score | Randomization, 8 weeks | The Fatigue Associated with Depression (FAsD) is a participant-rated scale with a total of 13 items. Six of the 13 items ask how often participants experience different aspects of fatigue with responses from 1 (never) to 5 (always). Seven of the 13 items ask how often fatigue impacts various aspects of the participant's lives with responses from 1 (not at all) to 5 (very much). The impact subscale score was derived by taking the mean of Items 7 through 13 (applicable items only). Item 12 applied only to participants with a spouse or significant other, and Item 13 applied to participants who had a job or who went to school. The FAsD impact subscale score ranges from 1 to 5. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline subscale score, treatment-by-visit, and baseline subscale score-by-visit. |
| Probability of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 at Week 8 | 8 weeks | A Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than or equal to 10 was defined as remission criteria. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). A categorical repeated measures analysis modeled the probability of remission at each visit, and the estimated probabilities were adjusted for treatment, visit, baseline MADRS total score, and treatment-by-visit. |
| Percentage of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 for at Least 2 Consecutive Measurements, Including the Participant's Last Measurement | Randomization up to 8 weeks | A Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than or equal to 10 for at least 2 consecutive measurements, including the participant's last measurement was defined as remission criteria at last 2 consecutive visits. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Percentage of participants was calculated by dividing the number of participants who meet criteria for remission at last 2 consecutive visits by the total number of participants analyzed, multiplied by 100%. |
| Change From Randomization to Week 8 in Hospital and Anxiety and Depression Scale (HADS) Anxiety Subscale Score | Randomization, 8 weeks | The Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item was rated on a 4-point scale (0-3), giving maximum scores of 21 for anxiety and depression subscale. Scores of 11 or more on either subscale were considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7 represent 'normal'. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline subscale score, treatment-by-visit, and baseline subscale score-by-visit. |
| Probability of Participants Who Have a Greater Than or Equal to 50 Percent Improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 | 8 weeks | A greater than or equal to 50 percent improvement (that is, a decrease from baseline) in the Montgomery-Asberg Depression Rating Scale (MADRS) total score was defined as response criteria. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). A categorical repeated measures analysis modeled the probability of response at each visit, and the estimated probabilities were adjusted for treatment, visit, baseline MADRS total score, and treatment-by-visit. |
| Change From Randomization to Week 8 in The Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score | Randomization, 8 weeks | The Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item was rated on a 4-point scale (0-3), giving maximum scores of 21 for anxiety and depression subscale. Scores of 11 or more on either subscale were considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7 represent 'normal'. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline subscale score, treatment-by-visit, and baseline subscale score-by-visit. |
| Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Randomization, 8 weeks | The Montgomery-Asberg Depression Rating Scale (MADRS) is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline item score, treatment-by-visit and baseline item score-by-visit. |
| Change From Randomization to Week 8 in Clinical Global Impressions of Severity (CGI-S) | Randomization, 8 weeks | Clinical Global Impression - Severity (CGI-S) measures severity of depression at the time of assessment compared with the start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit. |
| Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Global Functional Impairment Score | Randomization, 8 weeks | The Sheehan Disability Scale (SDS) was completed by the participant and used to assess the effect of the participant's symptoms on their work (Item 1), social (Item 2), and family life (Item 3). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. The Global Functional Impairment Score is the sum of the 3 items, and scores ranged from 0 to 30 with higher values indicating greater disruption in the participant's work life (work/school impairment score), social life (social life/leisure activities impairment score), and family life (family life/home responsibilities impairment score). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit. |
| Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Items | Randomization, 8 weeks | The Sheehan Disability Scale (SDS) was completed by the participant and used to assess the effect of the participant's symptoms on their work (work/school impairment score), social life (social life/leisure activities impairment score), and family life (family life/home responsibilities impairment score). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline item score, treatment-by-visit, and baseline item score-by-visit. |
| Change From Randomization to Week 8 in the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) | Randomization, 8 weeks | The Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) is a self-administered, 16-item questionnaire measuring degree of enjoyment and satisfaction experienced in various areas of daily life during the past week on a 5-point Likert scale (1=very poor and 5=very good). The total raw score is the sum of Items 1 to 14 and ranges from 14 to 70. The raw scores are converted to and expressed as the percentage of the maximum possible score. Higher scores indicate higher levels of enjoyment/satisfaction. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit. |
| Change From Randomization to Week 8 in the EuroQol Questionnaire-5 Dimension (EQ-5D) | Randomization, 8 weeks | The EQ-5D Visual Analog Scale is a generic, multidimensional, health-related, quality-of-life instrument. Overall health state score is self-reported using a visual analogue scale, marked on a scale of 0 to 100 with 0 representing worst imaginable health state and 100 representing best imaginable health state. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit. |
| Percentage of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Randomization up to 8 weeks | The Columbia-Suicide Severity Rating Scale (C-SSRS) captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation was defined as a yes answer to any 1 of 5 suicidal ideation questions, which included a wish to be dead and 4 different categories of active suicidal ideation. Suicidal behavior was defined as a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation and behavior are defined as treatment-emergent (TE) if not present at baseline. Percentage of participants was calculated by dividing the number of participants with suicide-related TE events by the total number of participants at risk, multiplied by 100%. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Event module. |
| Change From Randomization to Week 8 in Arizona Sexual Experiences (ASEX) Scale | Randomization, 8 weeks | The Arizona Sexual Experiences (ASEX) scale was used to assess sexual functioning in both males and females. The ASEX total score for the male and female version was calculated as the sum of the responses (rated from 1 \[extremely\] to 6 \[no/never\]) of the 5 items of the ASEX scale. Total scores ranged from 5 to 30, with higher scores indicating greater sexual dysfunction. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit. |
| Change From Randomization to Week 8 in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) | Randomization, 8 weeks | The Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) is a 7-item participant-rated questionnaire pertaining to a participant's cognitive and physical well-being. It assesses motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity. Each item was scored on a 6-point scale ranging from 1 (greater than normal) to 6 (totally absent). Total scores ranged from 7 to 42. Higher scores indicate greater disease severity. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit. |
| Change From Randomization to Week 8 in Blood Pressure | Randomization, 8 weeks | Blood pressure measurements were collected when the participant was in a sitting position. Three measurements of sitting blood pressure collected at approximately 1-minute intervals at every visit were averaged and used as the value for the visit. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline value, treatment-by-visit, and baseline value-by-visit. |
| Change From Randomization to Week 8 in Pulse Rate | Randomization, 8 weeks | Pulse measurements were collected when the participant was in a sitting position. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline value, treatment-by-visit, and baseline value-by-visit. |
| Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Average Score and Experience Subscale Score | Randomization, 8 weeks | The Fatigue Associated with Depression (FAsD) is a participant-rated scale with a total of 13 items. Six of the 13 items ask how often participants experience different aspects of fatigue with responses from 1 (never) to 5 (always). Seven of the 13 items ask how often fatigue impacts various aspects of the participant's lives with responses from 1 (not at all) to 5 (very much). The experience subscale score was derived by taking the mean of Items 1 through 6, and the average score was the mean of Items 1 through 13 (derived by taking the mean of all applicable items for each participant). Item 12 applied only to participants with a spouse or significant other, and Item 13 applied to participants who had a job or who went to school. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit. |
Countries
Australia, Austria, Belgium, Germany, Sweden, United Kingdom, United States
Participant flow
Pre-assignment details
The first 3 weeks of the study was a double-blind Confirmation Phase during which participants continued to receive their SSRI with adjunctive placebo. If randomization criteria were met, participants were randomized to adjunctive LY2216684 or adjunctive placebo. If criteria were not met, participants continued on placebo to maintain the blind.
Participants by arm
| Arm | Count |
|---|---|
| LY2216684 + SSRI (Randomized Participants) LY2216684: 12 or 18 milligrams (mg), administered orally, once daily for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI) | 230 |
| Placebo + SSRI (Randomized Participants) Placebo: Administered orally, once daily for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI) | 219 |
| Placebo + SSRI (Non-randomized Participants) Placebo: Administered orally, once daily for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI) | 519 |
| Total | 968 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Adjunctive Treatment (AT) Phase, 8 Weeks | Adverse Event | 0 | 13 | 8 | 13 |
| Adjunctive Treatment (AT) Phase, 8 Weeks | Lack of Efficacy | 0 | 4 | 7 | 4 |
| Adjunctive Treatment (AT) Phase, 8 Weeks | Lost to Follow-up | 0 | 4 | 5 | 7 |
| Adjunctive Treatment (AT) Phase, 8 Weeks | Physician Decision | 0 | 1 | 0 | 1 |
| Adjunctive Treatment (AT) Phase, 8 Weeks | Protocol Violation | 0 | 5 | 2 | 5 |
| Adjunctive Treatment (AT) Phase, 8 Weeks | Sponsor Decision | 0 | 0 | 3 | 7 |
| Adjunctive Treatment (AT) Phase, 8 Weeks | Withdrawal by Subject | 0 | 8 | 8 | 24 |
| Confirmation (CF) Phase, 3 Weeks | Adverse Event | 24 | 0 | 0 | 0 |
| Confirmation (CF) Phase, 3 Weeks | Lack of Efficacy | 6 | 0 | 0 | 0 |
| Confirmation (CF) Phase, 3 Weeks | Lost to Follow-up | 5 | 0 | 0 | 0 |
| Confirmation (CF) Phase, 3 Weeks | Physician Decision | 2 | 0 | 0 | 0 |
| Confirmation (CF) Phase, 3 Weeks | Protocol Violation | 16 | 0 | 0 | 0 |
| Confirmation (CF) Phase, 3 Weeks | Sponsor Decision | 3 | 0 | 0 | 0 |
| Confirmation (CF) Phase, 3 Weeks | Withdrawal by Subject | 32 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Placebo + SSRI (Non-randomized Participants) | Placebo + SSRI (Randomized Participants) | LY2216684 + SSRI (Randomized Participants) | Total |
|---|---|---|---|---|
| Age, Continuous | 47.39 years STANDARD_DEVIATION 12.68 | 48.44 years STANDARD_DEVIATION 11.39 | 48.29 years STANDARD_DEVIATION 11.9 | 47.84 years STANDARD_DEVIATION 12.21 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 31 Participants | 12 Participants | 19 Participants | 62 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 370 Participants | 158 Participants | 164 Participants | 692 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 118 Participants | 49 Participants | 47 Participants | 214 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 3 Participants | 0 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) Asian | 3 Participants | 1 Participants | 2 Participants | 6 Participants |
| Race (NIH/OMB) Black or African American | 53 Participants | 31 Participants | 17 Participants | 101 Participants |
| Race (NIH/OMB) More than one race | 2 Participants | 2 Participants | 4 Participants | 8 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 457 Participants | 185 Participants | 207 Participants | 849 Participants |
| Region of Enrollment Australia | 84 Participants | 20 Participants | 22 Participants | 126 Participants |
| Region of Enrollment Austria | 25 Participants | 10 Participants | 10 Participants | 45 Participants |
| Region of Enrollment Belgium | 13 Participants | 4 Participants | 7 Participants | 24 Participants |
| Region of Enrollment Germany | 95 Participants | 63 Participants | 58 Participants | 216 Participants |
| Region of Enrollment Sweden | 77 Participants | 18 Participants | 21 Participants | 116 Participants |
| Region of Enrollment United Kingdom | 30 Participants | 15 Participants | 19 Participants | 64 Participants |
| Region of Enrollment United States | 195 Participants | 89 Participants | 93 Participants | 377 Participants |
| Sex: Female, Male Female | 354 Participants | 145 Participants | 155 Participants | 654 Participants |
| Sex: Female, Male Male | 165 Participants | 74 Participants | 75 Participants | 314 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 270 / 1,052 | 87 / 228 | 44 / 218 | 128 / 519 | 5 / 18 | 39 / 206 | 22 / 202 | 70 / 482 |
| serious Total, serious adverse events | 9 / 1,052 | 7 / 228 | 7 / 218 | 12 / 519 | 1 / 18 | 2 / 206 | 4 / 202 | 4 / 482 |
Outcome results
Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
The Montgomery-Asberg Depression Rating Scale (MADRS) is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Time frame: Randomization, 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LY2216684 + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | -8.73 units on a scale | Standard Error 0.55 |
| Placebo + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | -8.49 units on a scale | Standard Error 0.57 |
Change From Randomization to Week 8 in Arizona Sexual Experiences (ASEX) Scale
The Arizona Sexual Experiences (ASEX) scale was used to assess sexual functioning in both males and females. The ASEX total score for the male and female version was calculated as the sum of the responses (rated from 1 \[extremely\] to 6 \[no/never\]) of the 5 items of the ASEX scale. Total scores ranged from 5 to 30, with higher scores indicating greater sexual dysfunction. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Time frame: Randomization, 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LY2216684 + SSRI | Change From Randomization to Week 8 in Arizona Sexual Experiences (ASEX) Scale | -0.92 units on a scale | Standard Error 0.25 |
| Placebo + SSRI | Change From Randomization to Week 8 in Arizona Sexual Experiences (ASEX) Scale | -0.68 units on a scale | Standard Error 0.26 |
Change From Randomization to Week 8 in Blood Pressure
Blood pressure measurements were collected when the participant was in a sitting position. Three measurements of sitting blood pressure collected at approximately 1-minute intervals at every visit were averaged and used as the value for the visit. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline value, treatment-by-visit, and baseline value-by-visit.
Time frame: Randomization, 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + SSRI | Change From Randomization to Week 8 in Blood Pressure | Systolic blood pressure | 3.09 millimeters of mercury (mmHg) | Standard Error 0.67 |
| LY2216684 + SSRI | Change From Randomization to Week 8 in Blood Pressure | Diastolic blood pressure | 4.54 millimeters of mercury (mmHg) | Standard Error 0.53 |
| Placebo + SSRI | Change From Randomization to Week 8 in Blood Pressure | Systolic blood pressure | 0.27 millimeters of mercury (mmHg) | Standard Error 0.69 |
| Placebo + SSRI | Change From Randomization to Week 8 in Blood Pressure | Diastolic blood pressure | 0.53 millimeters of mercury (mmHg) | Standard Error 0.54 |
Change From Randomization to Week 8 in Clinical Global Impressions of Severity (CGI-S)
Clinical Global Impression - Severity (CGI-S) measures severity of depression at the time of assessment compared with the start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Time frame: Randomization, 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LY2216684 + SSRI | Change From Randomization to Week 8 in Clinical Global Impressions of Severity (CGI-S) | -1.08 units on a scale | Standard Error 0.08 |
| Placebo + SSRI | Change From Randomization to Week 8 in Clinical Global Impressions of Severity (CGI-S) | -1.02 units on a scale | Standard Error 0.08 |
Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Average Score and Experience Subscale Score
The Fatigue Associated with Depression (FAsD) is a participant-rated scale with a total of 13 items. Six of the 13 items ask how often participants experience different aspects of fatigue with responses from 1 (never) to 5 (always). Seven of the 13 items ask how often fatigue impacts various aspects of the participant's lives with responses from 1 (not at all) to 5 (very much). The experience subscale score was derived by taking the mean of Items 1 through 6, and the average score was the mean of Items 1 through 13 (derived by taking the mean of all applicable items for each participant). Item 12 applied only to participants with a spouse or significant other, and Item 13 applied to participants who had a job or who went to school. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Time frame: Randomization, 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + SSRI | Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Average Score and Experience Subscale Score | FAsD average score | -0.62 units on a scale | Standard Error 0.06 |
| LY2216684 + SSRI | Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Average Score and Experience Subscale Score | FAsD experience subscale score | -0.57 units on a scale | Standard Error 0.06 |
| Placebo + SSRI | Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Average Score and Experience Subscale Score | FAsD average score | -0.55 units on a scale | Standard Error 0.06 |
| Placebo + SSRI | Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Average Score and Experience Subscale Score | FAsD experience subscale score | -0.50 units on a scale | Standard Error 0.06 |
Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Impact Subscale Score
The Fatigue Associated with Depression (FAsD) is a participant-rated scale with a total of 13 items. Six of the 13 items ask how often participants experience different aspects of fatigue with responses from 1 (never) to 5 (always). Seven of the 13 items ask how often fatigue impacts various aspects of the participant's lives with responses from 1 (not at all) to 5 (very much). The impact subscale score was derived by taking the mean of Items 7 through 13 (applicable items only). Item 12 applied only to participants with a spouse or significant other, and Item 13 applied to participants who had a job or who went to school. The FAsD impact subscale score ranges from 1 to 5. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline subscale score, treatment-by-visit, and baseline subscale score-by-visit.
Time frame: Randomization, 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LY2216684 + SSRI | Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Impact Subscale Score | -0.69 units on a scale | Standard Error 0.06 |
| Placebo + SSRI | Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Impact Subscale Score | -0.59 units on a scale | Standard Error 0.07 |
Change From Randomization to Week 8 in Hospital and Anxiety and Depression Scale (HADS) Anxiety Subscale Score
The Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item was rated on a 4-point scale (0-3), giving maximum scores of 21 for anxiety and depression subscale. Scores of 11 or more on either subscale were considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7 represent 'normal'. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline subscale score, treatment-by-visit, and baseline subscale score-by-visit.
Time frame: Randomization, 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LY2216684 + SSRI | Change From Randomization to Week 8 in Hospital and Anxiety and Depression Scale (HADS) Anxiety Subscale Score | -2.20 units on a scale | Standard Error 0.22 |
| Placebo + SSRI | Change From Randomization to Week 8 in Hospital and Anxiety and Depression Scale (HADS) Anxiety Subscale Score | -1.78 units on a scale | Standard Error 0.23 |
Change From Randomization to Week 8 in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)
The Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) is a 7-item participant-rated questionnaire pertaining to a participant's cognitive and physical well-being. It assesses motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity. Each item was scored on a 6-point scale ranging from 1 (greater than normal) to 6 (totally absent). Total scores ranged from 7 to 42. Higher scores indicate greater disease severity. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Time frame: Randomization, 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LY2216684 + SSRI | Change From Randomization to Week 8 in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) | -4.12 units on a scale | Standard Error 0.39 |
| Placebo + SSRI | Change From Randomization to Week 8 in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) | -3.68 units on a scale | Standard Error 0.4 |
Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items
The Montgomery-Asberg Depression Rating Scale (MADRS) is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline item score, treatment-by-visit and baseline item score-by-visit.
Time frame: Randomization, 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Apparent Sadness | -1.10 units on a scale | Standard Error 0.09 |
| LY2216684 + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Reported Sadness | -1.17 units on a scale | Standard Error 0.09 |
| LY2216684 + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Inner Tension | -0.72 units on a scale | Standard Error 0.08 |
| LY2216684 + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Reduced Sleep | -0.83 units on a scale | Standard Error 0.09 |
| LY2216684 + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Reduced Appetite | -0.54 units on a scale | Standard Error 0.08 |
| LY2216684 + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Concentration Difficulties | -1.07 units on a scale | Standard Error 0.09 |
| LY2216684 + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Lassitude | -1.11 units on a scale | Standard Error 0.09 |
| LY2216684 + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Inability to Feel | -1.17 units on a scale | Standard Error 0.09 |
| LY2216684 + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Pessimistic Thoughts | -0.88 units on a scale | Standard Error 0.08 |
| LY2216684 + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Suicidal Thoughts | -0.23 units on a scale | Standard Error 0.05 |
| Placebo + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Inability to Feel | -1.08 units on a scale | Standard Error 0.09 |
| Placebo + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Apparent Sadness | -1.26 units on a scale | Standard Error 0.09 |
| Placebo + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Concentration Difficulties | -0.82 units on a scale | Standard Error 0.09 |
| Placebo + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Reported Sadness | -1.19 units on a scale | Standard Error 0.09 |
| Placebo + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Suicidal Thoughts | -0.24 units on a scale | Standard Error 0.05 |
| Placebo + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Inner Tension | -0.71 units on a scale | Standard Error 0.09 |
| Placebo + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Lassitude | -0.98 units on a scale | Standard Error 0.09 |
| Placebo + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Reduced Sleep | -0.76 units on a scale | Standard Error 0.1 |
| Placebo + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Pessimistic Thoughts | -0.77 units on a scale | Standard Error 0.08 |
| Placebo + SSRI | Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items | Reduced Appetite | -0.72 units on a scale | Standard Error 0.08 |
Change From Randomization to Week 8 in Pulse Rate
Pulse measurements were collected when the participant was in a sitting position. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline value, treatment-by-visit, and baseline value-by-visit.
Time frame: Randomization, 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LY2216684 + SSRI | Change From Randomization to Week 8 in Pulse Rate | 9.64 beats per minute (bpm) | Standard Error 0.67 |
| Placebo + SSRI | Change From Randomization to Week 8 in Pulse Rate | -1.49 beats per minute (bpm) | Standard Error 0.69 |
Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Global Functional Impairment Score
The Sheehan Disability Scale (SDS) was completed by the participant and used to assess the effect of the participant's symptoms on their work (Item 1), social (Item 2), and family life (Item 3). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. The Global Functional Impairment Score is the sum of the 3 items, and scores ranged from 0 to 30 with higher values indicating greater disruption in the participant's work life (work/school impairment score), social life (social life/leisure activities impairment score), and family life (family life/home responsibilities impairment score). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Time frame: Randomization, 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LY2216684 + SSRI | Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Global Functional Impairment Score | -4.50 units on a scale | Standard Error 0.47 |
| Placebo + SSRI | Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Global Functional Impairment Score | -4.38 units on a scale | Standard Error 0.48 |
Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Items
The Sheehan Disability Scale (SDS) was completed by the participant and used to assess the effect of the participant's symptoms on their work (work/school impairment score), social life (social life/leisure activities impairment score), and family life (family life/home responsibilities impairment score). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline item score, treatment-by-visit, and baseline item score-by-visit.
Time frame: Randomization, 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + SSRI | Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Items | Work impairment score | -1.41 units on a scale | Standard Error 0.22 |
| LY2216684 + SSRI | Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Items | Social life impairment score | -1.64 units on a scale | Standard Error 0.17 |
| LY2216684 + SSRI | Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Items | Family life impairment score | -1.56 units on a scale | Standard Error 0.17 |
| Placebo + SSRI | Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Items | Work impairment score | -1.20 units on a scale | Standard Error 0.22 |
| Placebo + SSRI | Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Items | Social life impairment score | -1.53 units on a scale | Standard Error 0.17 |
| Placebo + SSRI | Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Items | Family life impairment score | -1.53 units on a scale | Standard Error 0.17 |
Change From Randomization to Week 8 in the EuroQol Questionnaire-5 Dimension (EQ-5D)
The EQ-5D Visual Analog Scale is a generic, multidimensional, health-related, quality-of-life instrument. Overall health state score is self-reported using a visual analogue scale, marked on a scale of 0 to 100 with 0 representing worst imaginable health state and 100 representing best imaginable health state. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Time frame: Randomization, 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LY2216684 + SSRI | Change From Randomization to Week 8 in the EuroQol Questionnaire-5 Dimension (EQ-5D) | 10.367 units on a scale | Standard Error 1.218 |
| Placebo + SSRI | Change From Randomization to Week 8 in the EuroQol Questionnaire-5 Dimension (EQ-5D) | 9.644 units on a scale | Standard Error 1.252 |
Change From Randomization to Week 8 in The Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score
The Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item was rated on a 4-point scale (0-3), giving maximum scores of 21 for anxiety and depression subscale. Scores of 11 or more on either subscale were considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7 represent 'normal'. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline subscale score, treatment-by-visit, and baseline subscale score-by-visit.
Time frame: Randomization, 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LY2216684 + SSRI | Change From Randomization to Week 8 in The Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score | -2.82 units on a scale | Standard Error 0.27 |
| Placebo + SSRI | Change From Randomization to Week 8 in The Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score | -2.64 units on a scale | Standard Error 0.27 |
Change From Randomization to Week 8 in the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)
The Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) is a self-administered, 16-item questionnaire measuring degree of enjoyment and satisfaction experienced in various areas of daily life during the past week on a 5-point Likert scale (1=very poor and 5=very good). The total raw score is the sum of Items 1 to 14 and ranges from 14 to 70. The raw scores are converted to and expressed as the percentage of the maximum possible score. Higher scores indicate higher levels of enjoyment/satisfaction. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Time frame: Randomization, 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LY2216684 + SSRI | Change From Randomization to Week 8 in the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) | 10.37 percentage of the maximum possible score | Standard Error 1.09 |
| Placebo + SSRI | Change From Randomization to Week 8 in the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) | 9.30 percentage of the maximum possible score | Standard Error 1.12 |
Percentage of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 for at Least 2 Consecutive Measurements, Including the Participant's Last Measurement
A Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than or equal to 10 for at least 2 consecutive measurements, including the participant's last measurement was defined as remission criteria at last 2 consecutive visits. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Percentage of participants was calculated by dividing the number of participants who meet criteria for remission at last 2 consecutive visits by the total number of participants analyzed, multiplied by 100%.
Time frame: Randomization up to 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| LY2216684 + SSRI | Percentage of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 for at Least 2 Consecutive Measurements, Including the Participant's Last Measurement | 20.89 percentage of participants |
| Placebo + SSRI | Percentage of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 for at Least 2 Consecutive Measurements, Including the Participant's Last Measurement | 17.89 percentage of participants |
Percentage of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
The Columbia-Suicide Severity Rating Scale (C-SSRS) captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation was defined as a yes answer to any 1 of 5 suicidal ideation questions, which included a wish to be dead and 4 different categories of active suicidal ideation. Suicidal behavior was defined as a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation and behavior are defined as treatment-emergent (TE) if not present at baseline. Percentage of participants was calculated by dividing the number of participants with suicide-related TE events by the total number of participants at risk, multiplied by 100%. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Event module.
Time frame: Randomization up to 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| LY2216684 + SSRI | Percentage of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | TE suicidal ideation | 4.46 percentage of participants |
| LY2216684 + SSRI | Percentage of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | TE suicidal behavior | 0.00 percentage of participants |
| Placebo + SSRI | Percentage of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | TE suicidal ideation | 5.96 percentage of participants |
| Placebo + SSRI | Percentage of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | TE suicidal behavior | 0.52 percentage of participants |
Probability of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 at Week 8
A Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than or equal to 10 was defined as remission criteria. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). A categorical repeated measures analysis modeled the probability of remission at each visit, and the estimated probabilities were adjusted for treatment, visit, baseline MADRS total score, and treatment-by-visit.
Time frame: 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LY2216684 + SSRI | Probability of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 at Week 8 | 0.313 probability | Standard Error 0.034 |
| Placebo + SSRI | Probability of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 at Week 8 | 0.251 probability | Standard Error 0.032 |
Probability of Participants Who Have a Greater Than or Equal to 50 Percent Improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8
A greater than or equal to 50 percent improvement (that is, a decrease from baseline) in the Montgomery-Asberg Depression Rating Scale (MADRS) total score was defined as response criteria. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). A categorical repeated measures analysis modeled the probability of response at each visit, and the estimated probabilities were adjusted for treatment, visit, baseline MADRS total score, and treatment-by-visit.
Time frame: 8 weeks
Population: All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LY2216684 + SSRI | Probability of Participants Who Have a Greater Than or Equal to 50 Percent Improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 | 0.357 probability | Standard Error 0.034 |
| Placebo + SSRI | Probability of Participants Who Have a Greater Than or Equal to 50 Percent Improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 | 0.352 probability | Standard Error 0.034 |